Myo antigen detection method combining ELISA and SERS
By combining ELISA and SERS technology, using gold nanoparticles and Raman signaling molecules to form a double-anti-sandwich structure, the problem of insufficient sensitivity and specificity in the existing Myo antigen detection methods is solved, and the rapid and convenient Myo antigen detection is achieved, improving the The accuracy of detection and ease of operation are provided.
Patent Information
- Application Number
- CN202411147931.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-12
AI Technical Summary
The existing Myo antigen detection methods lack high sensitivity and specificity, making it difficult to quickly and conveniently identify markers of acute myocardial infarction.
Combined with enzyme-linked immunosorbent assay (ELISA) and surface-enhanced Raman scattering (SERS) technology, a dual-anti-sandwich structure was formed by preparing gold nanoparticles and Raman signaling molecules, and a portable Raman spectrometer was used to detect the Raman signal value of Myo antigen. , achieve high sensitivity and specific recognition.
It realizes fast, convenient, high sensitivity and high specificity Myo antigen detection, taking into account quantitative analysis and molecular recognition capabilities, and improves the accuracy of detection and simplicity of operation.
Smart Images

Figure CN118937688A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biological detection, and in particular to a method for detecting Myo antigen, a myocardial infarction marker, by combining an enzyme-linked immunosorbent assay (ELISA) and surface enhanced Raman scattering (SERS). Background Art
[0002] Immunodiagnosis includes radioimmunoassay, enzyme-linked immunosorbent assay, chemiluminescence, etc. Among them, enzyme-linked immunosorbent assay has the characteristics of low cost and large-scale operation, and enzyme-linked immunosorbent assay (ELISA) is the most widely used technology, which has the advantages of rapidity, sensitivity, simplicity, and easy standardization. It has been widely used in the diagnosis of various bacterial and viral diseases.
[0003] Surface enhanced Raman spectroscopy is a spectral technique that uses the enhancement effect of metal nanostructures on Raman scattering signals. Since Fleischmann et al. discovered in 1974 that the Raman signal of pyridine molecules adsorbed on the surface of a rough silver electrode was greatly enhanced, SERS technology has developed rapidly and gradually become a powerful research tool in the field of surface science and electrochemistry. SERS technology has a wide range of applications in many fields, including biomedicine, environmental monitoring, food safety, etc., with the advantages of high sensitivity, high selectivity and non-destructiveness.
[0004] Acute myocardial infarction (AMI) is one of the most life-threatening acute coronary syndromes, causing the most severe heart discomfort. At present, creatine kinase isoenzyme (CK-MB), myoglobin (Myo), troponin T, and troponin I are valuable biomarkers for the diagnosis of AMI. Among them, Myo is recognized as a good marker for early myocardial injury. It can show abnormal increase within 1-3 hours of onset, which is the earliest and has high sensitivity. There are colorimetric, fluorescent, electrochemical, electrochemical and electrochemical methods for detecting Myo. These methods provide favorable conditions for obtaining qualitative and quantitative information of bioactive molecules, but lack high-specific molecular recognition capabilities.
[0005] Therefore, it is necessary to develop a faster, more convenient, more sensitive and more specific Myo antigen detection method. Summary of the invention
[0006] The purpose of the present invention is to overcome the defects of the prior art and provide a Myo antigen detection method combining ELISA and SERS. ELISA provides highly sensitive immune response and quantitative analysis, and SERS provides highly specific molecular recognition ability; the Raman signal value of the Raman signal molecule on the labeled antibody in the double antibody sandwich structure is used to determine whether the sample contains Myo antigen, and a portable Raman spectrometer can be used to achieve rapid detection of the antigen of Myo, a marker of acute myocardial infarction.
[0007] In order to achieve the above objectives, one of the technical solutions of the present invention is: a Myo antigen detection method combining ELISA and SERS, which specifically comprises the following steps:
[0008] S1: Preparation of gold nanoparticles;
[0009] S2: preparing Raman signal gold nanoparticles: diluting the gold nanoparticles prepared in step S1 and mixing them with the Raman signal molecule solution to obtain Raman signal gold nanoparticles;
[0010] S3: preparing immune signal gold nanoparticles: mixing the Raman signal gold nanoparticles prepared in step S1 with the myocardial infarction marker Myo antibody, and blocking the active sites to obtain immune signal gold nanoparticles;
[0011] S4: preparing a microtiter plate coated with antibodies: adding Myo antibodies to the ELISA microtiter plate for incubation, and sealing the unoccupied gaps to obtain a microtiter plate coated with antibodies;
[0012] S5: Preparation of double antibody sandwich structure: adding the sample to be tested and the immune signal gold nanoparticles prepared in step S3 to the antibody-coated microtiter plate prepared in step S4, respectively, mixing, incubating, and washing together to obtain a double antibody sandwich structure;
[0013] S6: Detection of Myo antigen: Perform Raman detection on the double antibody sandwich structure obtained in step S5 to obtain the Raman spectrum result of Myo antigen; qualitatively identify Myo antigen by Raman signal value, if the Raman signal value is ≤200cps, Myo antigen is blank; if the Raman signal value is >200cps, Myo antigen is positive.
[0014] ELISA microtiter plates can be modified by direct adsorption to antibodies that specifically recognize Myo antigens, and immune signal gold nanoparticles have the ability to express Raman signals and modify labeled antibodies.
[0015] In a preferred embodiment of the present invention, the method for preparing gold nanoparticles in step S1 is as follows: 150-250 ml of a 0.005-0.015 wt% chloroauric acid solution is heated to boiling under magnetic stirring, and then 1-4 ml of a 0.5-1.5 wt% sodium citrate solution is added to the boiling chloroauric acid solution, and the reaction is completed after boiling for 20-30 minutes, and then cooled to room temperature to obtain gold nanoparticles.
[0016] In a preferred embodiment of the present invention, the particle size of the gold nanoparticles in step S1 is 30-55 nm, and the ultraviolet absorption wavelength is 526 nm.
[0017] In a preferred embodiment of the present invention, the preparation method of Raman signal gold nanoparticles in step S2 is as follows: the gold nanoparticles are diluted 80-120 times with deionized water, the obtained gold nanoparticle solution is mixed with the Raman signal molecule solution at a volume ratio of 80-120:1, and then washed with a buffer solution and redispersed in the buffer solution to obtain Raman signal gold nanoparticles.
[0018] Further preferably, the Raman signal molecule includes but is not limited to IR808.
[0019] In a preferred embodiment of the present invention, the preparation method of the immune signal gold nanoparticles in step S3 is as follows: 20-50ul 4-6mM EDC and 20-30ul 4-6mM NHS are added to the Raman signal gold particles respectively, activated for 40-80min, and then 20ug-50ug Myo antibody is added, incubated at 2-6°C overnight, and after centrifugation, a blocking solution is added, reacted at room temperature for 0.5-1.5h to block the remaining active sites, and dispersed in the blocking solution again after centrifugation to obtain the immune signal gold nanoparticles.
[0020] Further preferably, the concentration of the Raman signal molecule solution is 0.01-100 mM, and the buffer includes but is not limited to 1-100 mM pH 5.5-8 citric acid-sodium citrate buffer (CPBS), boric acid-borax buffer (BB), citric acid-borax buffer (CBS), etc.
[0021] In a preferred embodiment of the present invention, the preparation method of the antibody-coated microtiter plate in step S4 is as follows: the purified antibody is diluted with PB at pH 5.5-8, and dripped into the microtiter plate, with the amount of antibody in each well being 100-600 ng, incubated at 37° C. for 2 h, washed once with PBS, wherein the PBS solution includes 0.1-0.3 M disodium hydrogen phosphate, 0.1-0.3 M sodium dihydrogen phosphate and 140-160 mM PB, and a blocking solution is added to block at 30-40° C. for 1-3 h to block the unoccupied gaps in the titration plate.
[0022] Further preferably, the blocking solution comprises 1-20 wt % BSA, 1-200 mM PB solution with a pH of 5.5-8, 15-100 mM inorganic chloride salt and 1-10 wt % surfactant.
[0023] More preferably, the surfactant includes but is not limited to TW-20, TW-60, TW-80, CHAPS, TRITON-X100, and the inorganic chloride salt includes but is not limited to NaCl, KCL, MgCl2.
[0024] In a preferred embodiment of the present invention, the preparation method of the double antibody sandwich structure in step S5 is as follows: the sample to be tested and the immune signal gold nanoparticles obtained in step S3 are respectively added to the antibody-coated microtiter plate obtained in step S4, mixed together, incubated at 30-50°C for 3-7 minutes, aspirated the solution in the titration plate, and washed with PBS-T to obtain a double antibody sandwich structure; the PBS-T solution is a mixed solution of PBS solution and TW-20, and the mass fraction of TW-20 in the PBS-T solution is 1-10wt%.
[0025] In a preferred embodiment of the present invention, in step S5, a double antibody sandwich structure is obtained in an ELISA microtiter plate, and after washing with PBS-T, aluminum foil is laid on the bottom of the plate for SERS detection.
[0026] In a preferred embodiment of the present invention, the Raman spectrometer in step S6 is a portable Raman spectrometer or other types of Raman spectrometers, and the excitation wavelength is preferably 785 nm.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] 1. The present invention constructs a dual-mode detection platform: ELISA provides highly sensitive immune response and quantitative analysis, while SERS provides highly specific molecular recognition capabilities, so that the present invention is fast, convenient, highly sensitive and highly specific, and can achieve fingerprint recognition;
[0029] 2. The present invention uses Myo antibody as a specific recognition element to specifically recognize Myo antigen. Compared with nucleic acid detection, blood specimens for antibody serological detection are easier to obtain and the specimen quality is guaranteed. The operation is simple and convenient. In addition, the coated-labeled antibody pair screened by the present invention can also greatly improve the accuracy of detection.
[0030] 3. Compared with the single SERS detection method, the modification of the capture antibody in the present invention is simpler. The antibody is directly coated on the ELISA microtiter plate by physical adsorption, and there is no need to prepare a substrate, so the operation is simpler. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a schematic diagram of the detection principle of the present invention. The coated antibody in the ELISA microtiter plate specifically binds to the Myo antigen and forms a double antibody sandwich structure through incubation and binding with the immune signal gold nanoparticles;
[0032] Figure 2 is the surface enhanced Raman spectra of different Myo antigen concentrations of the present invention;
[0033] Figure 3It is a bar graph of biomarker detection of different types of acute myocardial infarction according to the present invention. DETAILED DESCRIPTION
[0034] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is described in more detail below with reference to the accompanying drawings and specific embodiments, but the protection scope of the present invention is not limited to these embodiments.
[0035] A Myo antigen detection method combining ELISA and SERS specifically comprises the following steps:
[0036] S1: Preparation of gold nanoparticles;
[0037] S2: preparing Raman signal gold nanoparticles: diluting the gold nanoparticles prepared in step S1 and mixing them with the Raman signal molecule solution to obtain Raman signal gold nanoparticles;
[0038] S3: preparing immune signal gold nanoparticles: mixing the Raman signal gold nanoparticles prepared in step S1 with the myocardial infarction marker Myo antibody, and blocking the active sites to obtain immune signal gold nanoparticles;
[0039] S4: preparing a microtiter plate coated with antibodies: adding Myo antibodies to the ELISA microtiter plate for incubation, and sealing the unoccupied gaps to obtain a microtiter plate coated with antibodies;
[0040] S5: Preparation of double antibody sandwich structure: adding the sample to be tested and the immune signal gold nanoparticles prepared in step S3 to the antibody-coated microtiter plate prepared in step S4, respectively, mixing, incubating, and washing together to obtain a double antibody sandwich structure;
[0041] S6: Detection of Myo antigen: Perform Raman detection on the double antibody sandwich structure obtained in step S5 to obtain the Raman spectrum result of Myo antigen; qualitatively identify Myo antigen by Raman signal value, if the Raman signal value is ≤200cps, Myo antigen is blank; if the Raman signal value is >200cps, Myo antigen is positive.
[0042] The method for preparing gold nanoparticles in step S1 is as follows: 150-250 ml of a 0.005-0.015 wt % chloroauric acid solution is taken and heated to boiling under magnetic stirring, then 1-4 ml of a 0.5-1.5 wt % sodium citrate solution is taken and added to the boiling chloroauric acid solution, and the reaction is completed after boiling for 20-30 minutes, and then cooled to room temperature to obtain gold nanoparticles.
[0043] The particle size of the gold nanoparticles in step S1 is 30-55 nm, and the ultraviolet absorption wavelength is 526 nm.
[0044] The preparation method of the Raman signal gold nanoparticles in step S2 is as follows: dilute the gold nanoparticles with deionized water by 80-120 times, mix the obtained gold nanoparticle solution with the Raman signal molecule solution at a volume ratio of 80-120:1, wash with a buffer solution and then redisperse in the buffer solution to obtain Raman signal gold nanoparticles.
[0045] The Raman signal molecule includes but is not limited to IR808.
[0046] The concentration of the Raman signal molecule solution is 0.01-100 mM, and the buffer includes but is not limited to 1-100 mM pH 5.5-8 citric acid-sodium citrate buffer (CPBS), boric acid-borax buffer (BB), citric acid-borax buffer (CBS), etc.
[0047] The preparation method of the immune signal gold nanoparticles in step S3 is as follows: 20-50ul 4-6mM EDC and 20-30ul 4-6mM NHS are added to the Raman signal gold particles respectively, activated for 40-80min, and then 20ug-50ug Myo antibody is added, incubated at 2-6°C overnight, centrifuged, added with blocking solution, reacted at room temperature for 0.5-1.5h to block the remaining active sites, and dispersed again in the blocking solution after centrifugation to obtain the immune signal gold nanoparticles.
[0048] The method for preparing the antibody-coated microtiter plate in step S4 is as follows: the purified antibody is diluted with PB at pH 5.5-8, and dripped into the microtiter plate, with the antibody amount in each well being 100-600 ng, incubated at 37° C. for 2 h, and washed once with PBS, wherein the PBS solution includes 0.1-0.3 M disodium hydrogen phosphate, 0.1-0.3 M sodium dihydrogen phosphate and 140-160 mM PB, and a blocking solution is added to block at 30-40° C. for 1-3 h to block the unoccupied gaps in the microtiter plate.
[0049] The blocking solution includes 1-20 wt % BSA, 1-200 mM PB solution with pH 5.5-8, 15-100 mM inorganic chloride salt and 1-10 wt % surfactant.
[0050] The surfactant includes but is not limited to TW-20, TW-60, TW-80, CHAPS, TRITON-X100, and the inorganic chloride salt includes but is not limited to NaCl, KCL, MgCl2.
[0051] The preparation method of the double antibody sandwich structure in step S5 is as follows: the sample to be tested and the immune signal gold nanoparticles prepared in step S3 are added to the antibody-coated microtiter plate prepared in step S4, mixed together, incubated at 30-50° C. for 3-7 minutes, aspirated the solution in the titration plate, and washed with PBS-T to obtain the double antibody sandwich structure; the PBS-T solution is a mixed solution of PBS solution and TW-20, and the mass fraction of TW-20 in the PBS-T solution is 1-10wt%.
[0052] In step S5, a double antibody sandwich structure is obtained in an ELISA microtiter plate, and after washing with PBS-T, aluminum foil is laid on the bottom of the plate for SERS detection.
[0053] In step S6, the Raman spectrometer is a portable Raman spectrometer or other types of Raman spectrometers, and the excitation wavelength is preferably 785 nm.
[0054] Example 1
[0055] A Myo antigen detection method combining ELISA and SERS specifically comprises the following steps:
[0056] (1) Preparation of gold nanoparticles: 200 ml of 0.01% chloroauric acid solution was heated to boiling under magnetic stirring, and then 1.5 ml of 1% sodium citrate solution was added to the boiling chloroauric acid solution. The reaction was allowed to boil for 20 min and then cooled to room temperature to obtain gold nanoparticles with a particle size of 55 nm.
[0057] (2) Preparation of Raman signal gold nanoparticles: 9.875 ml of deionized water and 125 ul of gold nanoparticles were mixed and magnetically stirred. 100 ul of 500 μM IR808 Raman signal molecule solution was added and stirred at room temperature for 10 min. The mixture was washed twice with 50 mM pH 7.4 BB buffer and redispersed in BB buffer to obtain Raman signal gold nanoparticles.
[0058] (3) Preparation of immune signal gold nanoparticles: 20ul of 5mM EDC and 20ul of 5mM NHS were added to 1ml of the Raman signal gold nanoparticles prepared above for activation, reacted at room temperature for 1h, centrifuged, the supernatant was discarded, and redispersed in 200ul of 50mM BB buffer at pH 7.4, 20ug of labeled Myo antibody was added, incubated at 4°C overnight, centrifuged, the supernatant was discarded, and blocking solution was added to react at room temperature for 1h. After centrifugation again and the supernatant was discarded, the mixture was dispersed in 1ml of a blocking solution composed of 5wt% BSA, 0.2M PB at pH=7.4, 100mM sodium chloride and 1wt% TW-20 to obtain immune signal gold nanoparticles.
[0059] (4) Preparation of antibody-coated microtiter plates: The purified Myo antibody was diluted with PB at pH 7.4 and dripped into a microtiter plate with 100 ng of antibody per well. The plate was incubated at 37°C for 2 h, washed once with PBS at pH 7.3, and blocking solution was added to incubate at 37°C for 2 h to block the unoccupied spaces of the plate.
[0060] (5) Preparation of double antibody sandwich structure: After adding Myo antigens at four concentrations of 25 pg / ml, 50 pg / ml, 100 pg / ml, and 250 pg / ml to different titration plates, immune signal gold nanoparticles were added and mixed together, incubated at 40°C for 5 min, the solution in the titration plate was aspirated, and washed with 0.4% PBS-T to obtain a double antibody sandwich structure. At this time, the amount of immune gold nanoparticles with Raman signal molecules on the titration plate is proportional to the amount of antigen.
[0061] (6) Detection of Myo antigen: After obtaining the double antibody sandwich structure inside the ELISA microtiter plate, wash it with 0.4% PBS-T and absorb all the liquid, then lay a layer of aluminum foil on the bottom of the plate. Raman detection is directly performed by a portable Raman spectrometer (laser wavelength 785nm) with a test time of 10s, which can achieve rapid detection of Myo antigen. The Raman spectrum results are as follows: Figure 2 shown.
[0062] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some or all of the technical features thereof may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A Myo antigen detection method combining ELISA and SERS, characterized in that: The steps include: S1: Preparation of gold nanoparticles; S2: preparing Raman signal gold nanoparticles: diluting the gold nanoparticles prepared in step S1 and mixing them with the Raman signal molecule solution to obtain Raman signal gold nanoparticles; S3: preparing immune signal gold nanoparticles: mixing the Raman signal gold nanoparticles prepared in step S1 with the myocardial infarction marker Myo antibody, and blocking the active sites to obtain immune signal gold nanoparticles; S4: preparing a microtiter plate coated with antibodies: adding Myo antibodies to the ELISA microtiter plate for incubation, and sealing the unoccupied gaps to obtain a microtiter plate coated with antibodies; S5: Preparation of double antibody sandwich structure: adding the sample to be tested and the immune signal gold nanoparticles prepared in step S3 to the antibody-coated microtiter plate prepared in step S4, respectively, mixing, incubating, and washing together to obtain a double antibody sandwich structure; S6: Detection of Myo antigen: Perform Raman detection on the double antibody sandwich structure obtained in step S5 to obtain the Raman spectrum result of Myo antigen; qualitatively identify Myo antigen by Raman signal value, if the Raman signal value is ≤200cps, Myo antigen is blank; if the Raman signal value is >200cps, Myo antigen is positive.
2. The Myo antigen detection method combining ELISA and SERS as claimed in claim 1, characterized in that: The particle size of the gold nanoparticles in step S1 is 30-55 nm, and the ultraviolet absorption wavelength is 526 nm.
3. The Myo antigen detection method combining ELISA and SERS as claimed in claim 1, characterized in that: The preparation method of the Raman signal gold nanoparticles in step S2 is as follows: dilute the gold nanoparticles with deionized water by 80-120 times, mix the obtained gold nanoparticle solution with the Raman signal molecule solution at a volume ratio of 80-120:1, wash with a buffer solution and then redisperse in the buffer solution to obtain Raman signal gold nanoparticles.
4. The Myo antigen detection method combining ELISA and SERS as claimed in claim 3, characterized in that: The Raman signal molecule includes but is not limited to IR808, and the concentration of the Raman signal molecule solution is 0.01-100 mM.
5. The Myo antigen detection method combining ELISA and SERS as claimed in claim 1, characterized in that: The preparation method of the immune signal gold nanoparticles in step S3 is as follows: 20-50ul 4-6mM EDC and 20-30ul 4-6mM NHS are added to the Raman signal gold particles respectively, activated for 40-80min, and then 20ug-50ug Myo antibody is added, incubated at 2-6°C overnight, centrifuged and then added with blocking solution, reacted at room temperature for 0.5-1.5h to block the remaining active sites, and dispersed again in the blocking solution after centrifugation to obtain the immune signal gold nanoparticles.
6. The Myo antigen detection method combining ELISA and SERS according to claim 3 or 5, characterized in that: Buffers include, but are not limited to, 1-100 mM citric acid-sodium citrate buffer, boric acid-borax buffer, and citric acid-borax buffer at pH 5.5-8.
7. The Myo antigen detection method combining ELISA and SERS as claimed in claim 1, characterized in that: The preparation method of the antibody-coated microtiter plate in step S4 is as follows: the purified antibody is diluted with PB at pH 5.5-8, and dripped into the microtiter plate, with the antibody amount in each well being 100-600 ng, incubated at 37° C. for 2 h, and washed once with PBS, wherein the PBS solution includes 0.1-0.3 M disodium hydrogen phosphate, 0.1-0.3 M sodium dihydrogen phosphate and 140-160 mM PB, and a blocking solution is added to block at 30-40° C. for 1-3 h to block the unoccupied gaps in the titration plate.
8. The Myo antigen detection method combining ELISA and SERS according to claim 5 or 7, characterized in that: The blocking solution includes 1-20wt% BSA, 1-200mM PB solution with a pH of 5.5-8, 15-100mM inorganic chloride salt and 1-10wt% surfactant, wherein the surfactant includes but is not limited to TW-20, TW-60, TW-80, CHAPS, TRITON-X100, and the inorganic chloride salt includes but is not limited to NaCl, KCL, MgCl2.
9. The Myo antigen detection method combining ELISA and SERS as claimed in claim 1, characterized in that: The preparation method of the double antibody sandwich structure in step S5 is as follows: the sample to be tested and the immune signal gold nanoparticles prepared in step S3 are added to the antibody-coated microtiter plate prepared in step S4, mixed together, incubated at 30-50° C. for 3-7 minutes, aspirated the solution in the titration plate, and washed with PBS-T to obtain the double antibody sandwich structure; the PBS-T solution is a mixed solution of PBS solution and TW-20, and the mass fraction of TW-20 in the PBS-T solution is 1-10wt%.
10. The Myo antigen detection method combining ELISA and SERS according to claim 1, characterized in that: The Raman spectrometer in step S6 is a portable Raman spectrometer or other types of Raman spectrometers, and the excitation wavelength is 785 nm.
Citation Information
Patent Citations
Nucleic acid aptamer fluorescence sensor for detecting myoglobin and construction method thereof
CN110208548A
Carcino-embryonic antigen detection reagent and kit based on double-antibody sandwich chemiluminescence method
CN116165193A
SERS (Surface Enhanced Raman Scattering) detection kit for detecting tiny nucleic acid marker of acute myocardial infarction as well as preparation method and application of SERS detection kit
CN117757901A
Surface enhanced Raman scattering detection kit for detecting acute myocardial infarction protein marker as well as preparation method and application of surface enhanced Raman scattering detection kit
CN117761322A
Combinational surface-enhanced raman scattering probe and method for detecting target substance by using the same
KR1020100107648A
